Breaking News, Promotions & Moves

Foghorn Therapeutics Names Quintás-Cardama Chief Medical Officer

Quintás-Cardama previously served as head of clinical development for cell therapies at GSK.

Foghorn Therapeutics Inc., a clinical-stage biotechnology focused on medicines that treat serious disease by correcting abnormal gene expression, appointed Alfonso Quintás-Cardama, chief medical officer, effective September 11, 2023. Foghorn’s current CMO Sam Agresta, will retire from the company and will provide consulting services through early January 2024. Quintás-Cardama most recently was the CMO at TCR2 since 2017, where he led the development of the company’s cell therapy platform...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters